Trial
NCT04984811
NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
NeoImmuneTech
Collaborators
Roche Pharma AG
Condition
Carcinoma, Non-Small-Cell Lung
Intervention
efineptakin alfa
Why stopped
sponsor decision (not for safety)
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-11